Wegovy (semaglutide) for Weight Loss: A Comprehensive Guide

Introduction

If you are researching modern medical options for weight loss in the UK, you have likely encountered Wegovy (semaglutide). It has become one of the most talked-about prescription treatments for long-term weight management in adults. This comprehensive guide explains what Wegovy is, how it works, who may benefit, clinical evidence of its effectiveness, how to take it, possible side effects and precautions, how it compares with other treatments, and how to buy it safely from regulated UK pharmacies.

We also cover practical matters such as lifestyle changes to maximise results, injection technique and storage, interactions with other medicines, and a thorough FAQ section that answers common questions patients ask. The content is written for UK residents seeking safe, regulated pharmacy options and is intended to be medically informative while remaining accessible.

What is Wegovy (semaglutide)?

Wegovy is the brand name for a high-dose formulation of semaglutide, a glucagon‑like peptide‑1 (GLP‑1) receptor agonist. Semaglutide has been used at lower doses for type 2 diabetes (under brands such as Ozempic and Rybelsus), but Wegovy uses a higher fixed dose specifically licensed for chronic weight management in adults.

Wegovy is a prescription-only medication delivered as a once-weekly subcutaneous injection. It is intended as an adjunct to a reduced-calorie diet and increased physical activity for long-term weight management, under the supervision of a healthcare professional.

How Wegovy works: the medical mechanism explained

Wegovy (semaglutide) mimics the action of the naturally occurring hormone GLP‑1. GLP‑1 is released from the gut in response to food and has several actions that help regulate blood sugar and appetite. Semaglutide acts on GLP‑1 receptors in multiple parts of the body, producing effects that support weight loss:

Reduced appetite: Semaglutide acts on appetite centres in the hypothalamus and other brain areas to reduce hunger and cravings.
Early satiety: It increases feelings of fullness, so people eat less at meals.
Slowed gastric emptying: Semaglutide delays how quickly food leaves the stomach, extending the feeling of fullness after eating.
Metabolic effects: It enhances insulin secretion in a glucose-dependent manner and reduces glucagon secretion, improving glycaemic control in people with diabetes.
Impact on reward pathways: There is evidence semaglutide reduces hedonic (pleasure-driven) eating by modulating reward pathways in the brain.

Combined, these mechanisms help create a sustained reduction in energy intake, leading to clinically meaningful weight loss when used alongside lifestyle change.

Who is Wegovy for? Eligibility and clinical considerations

Wegovy is typically considered for adults who are overweight or living with obesity where lifestyle modification alone has not achieved or maintained adequate weight loss. Healthcare professionals usually assess suitability based on body mass index (BMI) and weight-related health conditions:

Common eligibility criteria used in clinical practice: BMI ≥30 kg/m² (obesity) or BMI ≥27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, obstructive sleep apnoea, or dyslipidaemia. Exact thresholds and access vary depending on individual clinical judgement and local guidelines.
Wegovy is intended for adults; paediatric use is not standard and requires specialist oversight.
It is not appropriate for people with a personal or family history of certain thyroid cancers (see precautions).

Whether you will be offered Wegovy will depend on a clinical assessment by a prescriber (GP, obesity specialist or private prescriber) who will consider medical history, medications, pregnancy plans, and other factors.

Clinical evidence: what the trials show

The evidence base for semaglutide in weight management comes mainly from the STEP clinical trial programme (Semaglutide Treatment Effect in People with obesity). These large, randomised controlled trials assessed weekly semaglutide 2.4 mg combined with lifestyle intervention, compared with placebo.

Key findings from the STEP studies included:

Significant weight loss: In adults without diabetes, weekly semaglutide 2.4 mg produced substantial mean weight loss over 68 weeks compared with placebo when combined with lifestyle support. Many participants achieved clinically meaningful weight loss (≥5%, ≥10% and ≥15% of baseline body weight).
Benefits in people with type 2 diabetes: Semaglutide also produced weight loss in people with type 2 diabetes, though the average percentage weight loss was generally lower than in people without diabetes.
Improvements in cardiometabolic risk factors: Trials reported improvements in waist circumference, blood pressure, glycaemic control and some lipid measures.
Maintenance and relapse: Trials that included withdrawal or off-treatment phases showed weight regain after stopping semaglutide, indicating that ongoing therapy or continued lifestyle strategies are needed to sustain results.

These trials underpin regulatory approvals and prescribing recommendations in many countries. Individual responses vary and close monitoring by a clinician is important.

Dosage and administration: step-up dosing schedule

Wegovy is given as a once-weekly subcutaneous injection. To improve tolerability, a stepwise dose escalation is commonly used until the recommended maintenance dose is reached. The typical regimen is:

Weeks 1–4: 0.25 mg once weekly (starting dose)
Weeks 5–8: 0.5 mg once weekly
Weeks 9–12: 1.0 mg once weekly
Weeks 13–16: 1.7 mg once weekly
Weeks 17 onwards: 2.4 mg once weekly (maintenance dose)

Patients who do not tolerate the dose escalation can remain at a lower dose; clinicians may individualise dosing. If a dose is missed, guidance from the product information should be followed (typically take the missed dose as soon as remembered if within a short time window, otherwise skip and take the next scheduled dose). Always follow your prescriber’s specific instructions.

Administration tips:

Wegovy is injected subcutaneously into the abdomen, thigh or upper arm.
Rotate injection sites to reduce local irritation and lipohypertrophy.
Pens typically contain multiple doses — check the pen instructions provided by the manufacturer and dispose of sharps safely in a pharmaceutical sharps bin.
Storage: store unopened pens in the refrigerator (2–8°C). Once in use, many pens can be kept at room temperature for a limited period — check the leaflet for exact storage times and temperature limits.

Side effects and common adverse reactions

Like all medicines, Wegovy can cause side effects. Many are related to its gastrointestinal effects and are often dose-dependent and transient during dose escalation.

Common side effects (occur in a substantial minority of patients):

Nausea
Vomiting
Diarrhoea or constipation
Abdominal pain or discomfort
Indigestion (dyspepsia)
Headache and fatigue (reported by some people)
Injection-site reactions such as redness, itching or bruising

Less common but important adverse effects and precautions:

Pancreatitis: There have been reports of acute pancreatitis with GLP‑1 receptor agonists. Seek immediate medical attention for severe persistent abdominal pain with or without vomiting.
Gallbladder disease: Rapid weight loss can increase the risk of gallstones and cholecystitis. If you develop right-sided abdominal pain, fever or jaundice, seek assessment.
Thyroid C‑cell tumours (rodent risk): In rodent studies, semaglutide caused C‑cell tumours of the thyroid. The relevance to humans is unknown but Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
Hypoglycaemia: In people with type 2 diabetes taking insulin or insulin secretagogues (e.g., sulfonylureas), adding Wegovy increases the risk of low blood sugar. Dose adjustments of other glucose‑lowering medicines may be needed.
Renal and hepatic considerations: Severe nausea and vomiting may lead to dehydration and worsen kidney function. Use caution in patients with severe renal impairment; monitor renal function if symptoms occur.
Pregnancy and breastfeeding: Wegovy is not recommended during pregnancy and breastfeeding—weight loss is undesirable during pregnancy and safety data are limited.

Always report side effects to your prescriber and seek urgent care for severe symptoms.

Precautions, contraindications and drug interactions

Before starting Wegovy, your prescriber will review your medical history and current medicines. Key considerations include:

Contraindications: Known hypersensitivity to semaglutide or any excipients; personal or family history of medullary thyroid carcinoma (MTC) or MEN2.
Pregnancy/breastfeeding: Avoid Wegovy during pregnancy and breastfeeding. Women planning pregnancy should discuss stopping Wegovy and alternative options.
Diabetes medications: If you have type 2 diabetes and take insulin, sulfonylureas or meglitinides, your clinician may need to reduce doses to prevent hypoglycaemia.
Oral medicines: Because semaglutide slows gastric emptying, it can affect the absorption of oral medications (for example, some antibiotics, oral contraceptives, and certain cardiovascular drugs). Clinicians may advise monitoring therapeutic drug levels where relevant or taking medicines at specific times.
Kidney disease: Monitor hydration and renal function if severe gastrointestinal adverse effects occur.
Alcohol and driving: Alcohol can worsen some GI side effects and may increase calorie intake. Dizziness or fatigue from side effects may affect activities like driving—follow medical advice.

Comparisons with other weight‑loss medicines and treatments

Understanding how Wegovy compares to alternatives helps inform patient choice.

Wegovy vs Ozempic

Both Wegovy and Ozempic contain semaglutide, but at different dosing and indications. Ozempic doses (commonly up to 1.0 mg weekly for type 2 diabetes) are lower than Wegovy’s 2.4 mg weekly weight-management dose. Some patients prescribed Ozempic for diabetes also experience weight loss, but Wegovy is specifically licensed and trialled for weight management.

Wegovy vs liraglutide (Saxenda)

Liraglutide (Saxenda) is another injectable GLP‑1 receptor agonist approved for weight management at a daily dose. Compared with weekly semaglutide, liraglutide is given daily and clinical trials have shown semaglutide 2.4 mg typically achieves greater average weight loss. However, individual tolerability and clinical suitability differ and cost, injection frequency and contraindications influence choice.

Wegovy vs tirzepatide (Zepbound/Mounjaro)

Tirzepatide, a dual GIP/GLP‑1 receptor agonist, has shown very impressive weight loss results in clinical trials. It is available for type 2 diabetes (Mounjaro) and has been developed for obesity (Zepbound in some markets). Availability, licensing and local guidance vary: clinicians will consider the evidence, individual comorbidities and access when recommending options.

Medications vs surgical options

For people with severe obesity or those who have not achieved adequate weight loss with medical management, bariatric surgery (e.g., gastric bypass, sleeve gastrectomy) may be recommended. Surgery typically produces substantial and sustained weight loss but has surgical risks. Semaglutide may be used as part of a broader strategy or as an alternative for those not eligible or unwilling to undergo surgery.

Combining Wegovy with lifestyle changes: diet, exercise and behavioural support

Wegovy is licensed as an adjunct to lifestyle modification and is most effective when combined with structured diet and exercise support. Medication facilitates weight loss by reducing appetite and caloric intake, but long-term success requires sustainable behaviour changes.

Practical lifestyle measures to combine with treatment:

Calorie management: Aim for a realistic calorie deficit tailored by a healthcare professional or dietitian. Very low-calorie diets are not routinely recommended without supervision.
Balanced nutrition: Emphasise high-quality protein, plenty of vegetables, whole grains, healthy fats and limited processed foods and sugary drinks.
Meal planning and portion control: Use smaller plates, measure portions, and prepare meals to avoid reliance on convenience foods.
Mindful eating: Slow down, avoid distractions while eating, and be aware of hunger and fullness cues.
Physical activity: Aim for a mix of cardiovascular exercise and strength training. Even moderate increases in daily activity (e.g., brisk walking) improve outcomes.
Behavioural and psychological support: Cognitive behavioural strategies, coaching, group programmes and regular follow-up improve adherence and help manage emotional eating.
Sleep and stress: Address poor sleep and chronic stress, both of which can undermine weight loss.

Work with your GP, obesity specialist or a registered dietitian to create an individualised plan and set realistic goals.

How to buy Wegovy safely in the UK: regulated pharmacies and prescriptions

Wegovy is a prescription-only medicine in the UK. It is essential to obtain it through regulated, legitimate channels to ensure you receive a genuine product and appropriate clinical oversight.

Key safety points when buying Wegovy:

Prescription requirement: You must have a valid prescription from a UK prescriber (GP, NHS specialist or private prescriber). Beware of sellers offering to supply Wegovy without a prescription.
MHRA and licensing: Ensure the medicine supplied is a licensed product. The MHRA (Medicines and Healthcare products Regulatory Agency) regulates medicines in the UK. Only medications with appropriate UK marketing authorisation should be dispensed for use in the UK.
Pharmacy regulation: Confirm the online pharmacy is registered with the General Pharmaceutical Council (GPhC). Legitimate UK online pharmacies will display their GPhC registration details and have a registered responsible pharmacist to answer queries.
Contactable prescriber and pharmacist: Reputable services provide access to a prescriber for a clinical consultation and a pharmacist for advice on administration, storage and safety.
Clear product labelling and patient information: The product should include a patient information leaflet and clear instructions for use and disposal.
Avoid social-media and international marketplaces: Buying from unregulated websites or social media sellers risks counterfeit, contaminated or improperly stored medicines. These may be ineffective or dangerous.
Data privacy and payment security: Use sites with secure payment methods and clear privacy policies. Keep records of prescriptions and communications with prescribers.

If you have doubts about an online pharmacy, check the GPhC register and consider contacting the GPhC or MHRA for advice. Your safety should be the priority.

Injection technique and storage (practical patient guidance)

Before using Wegovy, receive instruction on injection technique from a pharmacist or nurse. General points:

Wash your hands and check the pen for damage or discoloration.
Allow refrigerated pens to reach room temperature if advised in the patient leaflet before injection.
Choose an injection site (abdomen, thigh, upper arm) and rotate sites each week or within the area to avoid repeated injection to the same spot.
Clean the area with an alcohol wipe if required and inject subcutaneously at a 45°–90° angle depending on needle length and subcutaneous tissue.
Dispose of used needles in an approved sharps container; do not dispose of them in household waste.
Keep a record of injection dates to maintain weekly dosing schedule.

Storage details: Unopened pens are usually stored in the fridge between 2–8°C. Once in use, follow the manufacturer leaflet for how long the pen can be kept out of the refrigerator and at what temperature. Do not freeze the pens.

Common questions — FAQ

Q: How quickly will I lose weight on Wegovy?

A: Individual responses vary. Many people begin to notice reduced appetite within weeks, and meaningful weight loss tends to be seen over months. Clinical trials reported substantial weight loss over 68 weeks. Early weeks may bring modest loss and longer-term treatment (months) is often required to achieve large percentage reductions in body weight.

Q: Will I regain weight when I stop Wegovy?

A: Trials show weight regain can occur after stopping semaglutide if lifestyle measures are not sustained. Long-term strategies—diet, exercise, behavioural support—are essential. Some patients may require ongoing medical follow-up to maintain weight loss.

Q: Can I take Wegovy if I have type 2 diabetes?

A: Wegovy can be used in people with type 2 diabetes, but your diabetes medicines may require adjustment to reduce hypoglycaemia risk. Discuss with your prescriber and monitor blood glucose closely during treatment initiation and dose changes.

Q: Is Wegovy available on the NHS?

A: Access to Wegovy on the NHS varies by local commissioning policies and current guidance. In many areas, Wegovy is prescribed as a private medication or through specialist services. Discuss local options with your GP and weight-management services.

Q: Can people who are pregnant or planning pregnancy take Wegovy?

A: No. Wegovy is not recommended during pregnancy or breastfeeding. Women planning pregnancy should discuss stopping the medicine and alternative approaches with their clinician.

Q: What should I do if I experience severe side effects?

A: Stop the medication and seek urgent medical attention for severe abdominal pain (possible pancreatitis), severe allergic reaction, breathing difficulty, or signs of gallbladder disease. For other severe or persistent side effects, contact your prescriber promptly.

Q: How do I know an online pharmacy is legitimate?

A: In the UK, ensure the pharmacy is registered with the General Pharmaceutical Council (GPhC). A legitimate UK online pharmacy will display GPhC registration details, have contactable clinical staff and require a valid prescription. Avoid sites that promise to supply prescription medicines without a prescription.

Q: Can young adults or adolescents use Wegovy?

A: Wegovy is intended for adults. Use in younger populations should only occur under specialist paediatric or adolescent obesity services and according to local regulations and licencing.

Q: What is the difference between Wegovy and Ozempic?

A: Both are semaglutide but at different doses and licence indications. Wegovy is formatted and dosed for weight management (2.4 mg weekly), while Ozempic is licensed for improving blood glucose in type 2 diabetes at lower doses. Always use the medicine prescribed for your condition and follow clinician instructions.

Summary and final considerations

Wegovy (semaglutide 2.4 mg weekly) is a powerful tool in the medical management of obesity when used alongside dietary, exercise and behavioural interventions. Clinical trials demonstrate clinically significant weight loss and improvements in cardiometabolic risk factors for many people. However, Wegovy is not a stand-alone cure: ongoing lifestyle change and medical follow-up are essential to achieve and maintain benefits.

Before starting Wegovy, a careful assessment by a prescriber is necessary to discuss risks, benefits, contraindications and monitoring. Side effects—particularly gastrointestinal effects—are common, and serious but rare adverse events like pancreatitis and gallbladder disease require vigilance.

When buying Wegovy in the UK, use only regulated channels: prescriptions from a qualified prescriber and supply through GPhC‑registered pharmacies providing MHRA‑licensed products. Avoid unregulated online sellers and social-media supply chains that risk counterfeit or unsafe medicines.

If you are considering Wegovy, discuss it with your GP or an obesity specialist. They can help you weigh the options, consider alternatives (including other pharmacotherapies or surgical referral), and arrange appropriate monitoring and support.

Disclaimer

Important: This article is for educational purposes only and does not constitute medical advice. It is not a substitute for consultation with a qualified healthcare professional. Always follow the guidance of your prescriber, pharmacist and local healthcare services. If you have questions about whether Wegovy is appropriate for you, speak to your GP or a specialist clinician. In the event of a medical emergency or severe symptoms, seek urgent medical care.